Logo image of BDSI

BIODELIVERY SCIENCES INTL (BDSI) Stock Fundamental Analysis

NASDAQ:BDSI - Nasdaq - Common Stock

5.59  0 (-0.09%)

After market: 5.6 +0.01 (+0.18%)

Fundamental Rating

3

Overall BDSI gets a fundamental rating of 3 out of 10. We evaluated BDSI against 195 industry peers in the Pharmaceuticals industry. The financial health of BDSI is average, but there are quite some concerns on its profitability. BDSI shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BDSI was profitable.
BDSI Yearly Net Income VS EBIT VS OCF VS FCFBDSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M

1.2 Ratios

Industry RankSector Rank
ROA 26.14%
ROE 45.18%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BDSI Yearly ROA, ROE, ROICBDSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 100 -100 200 300

1.3 Margins

Industry RankSector Rank
OM 22.27%
PM (TTM) 50.91%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDSI Yearly Profit, Operating, Gross MarginsBDSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for BDSI has been reduced compared to 1 year ago.
Compared to 1 year ago, BDSI has an improved debt to assets ratio.
BDSI Yearly Shares OutstandingBDSI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M
BDSI Yearly Total Debt VS Total AssetsBDSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M

2.2 Solvency

BDSI has an Altman-Z score of 2.65. This is not the best score and indicates that BDSI is in the grey zone with still only limited risk for bankruptcy at the moment.
A Debt/Equity ratio of 0.29 indicates that BDSI is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Altman-Z 2.65
ROIC/WACCN/A
WACCN/A
BDSI Yearly LT Debt VS Equity VS FCFBDSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M 150M

2.3 Liquidity

BDSI has a Current Ratio of 2.45. This indicates that BDSI is financially healthy and has no problem in meeting its short term obligations.
BDSI has a Quick Ratio of 2.17. This indicates that BDSI is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 2.17
BDSI Yearly Current Assets VS Current LiabilitesBDSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M

More info and screens

9

3. Growth

3.1 Past

BDSI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 232.00%, which is quite impressive.
Measured over the past years, BDSI shows a very strong growth in Earnings Per Share. The EPS has been growing by 71.95% on average per year.
BDSI shows a small growth in Revenue. In the last year, the Revenue has grown by 6.54%.
Measured over the past years, BDSI shows a very strong growth in Revenue. The Revenue has been growing by 60.81% on average per year.
EPS 1Y (TTM)232%
EPS 3Y37.54%
EPS 5Y71.95%
EPS Q2Q%520%
Revenue 1Y (TTM)6.54%
Revenue growth 3Y44.2%
Revenue growth 5Y60.81%
Sales Q2Q%2.33%

3.2 Future

The Earnings Per Share is expected to grow by 21.10% on average over the next years. This is a very strong growth
BDSI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.45% yearly.
EPS Next Y-57.48%
EPS Next 2Y-11.49%
EPS Next 3Y8.73%
EPS Next 5Y21.1%
Revenue Next Year22.27%
Revenue Next 2Y24.06%
Revenue Next 3Y23.25%
Revenue Next 5Y23.45%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BDSI Yearly Revenue VS EstimatesBDSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
BDSI Yearly EPS VS EstimatesBDSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1 -1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 6.73 indicates a rather cheap valuation of BDSI.
When comparing the Price/Earnings ratio of BDSI to the average of the S&P500 Index (26.91), we can say BDSI is valued rather cheaply.
A Price/Forward Earnings ratio of 15.84 indicates a correct valuation of BDSI.
BDSI is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 21.46, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 6.73
Fwd PE 15.84
BDSI Price Earnings VS Forward Price EarningsBDSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11.15
BDSI Per share dataBDSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)0.09
EPS Next 2Y-11.49%
EPS Next 3Y8.73%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BDSI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIODELIVERY SCIENCES INTL

NASDAQ:BDSI (3/22/2022, 8:00:02 PM)

After market: 5.6 +0.01 (+0.18%)

5.59

0 (-0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-09 2022-03-09/amc
Earnings (Next)05-04 2022-05-04
Inst Owners0.12%
Inst Owner Change0%
Ins Owners2.45%
Ins Owner Change0%
Market Cap552.29M
Analysts73.85
Price Target5.48 (-1.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 6.73
Fwd PE 15.84
P/S 3.31
P/FCF N/A
P/OCF N/A
P/B 2.94
P/tB N/A
EV/EBITDA 11.15
EPS(TTM)0.83
EY14.85%
EPS(NY)0.35
Fwd EY6.31%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.69
BVpS1.9
TBVpSN/A
PEG (NY)N/A
PEG (5Y)0.09
Profitability
Industry RankSector Rank
ROA 26.14%
ROE 45.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 22.27%
PM (TTM) 50.91%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.45
Quick Ratio 2.17
Altman-Z 2.65
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)232%
EPS 3Y37.54%
EPS 5Y71.95%
EPS Q2Q%520%
EPS Next Y-57.48%
EPS Next 2Y-11.49%
EPS Next 3Y8.73%
EPS Next 5Y21.1%
Revenue 1Y (TTM)6.54%
Revenue growth 3Y44.2%
Revenue growth 5Y60.81%
Sales Q2Q%2.33%
Revenue Next Year22.27%
Revenue Next 2Y24.06%
Revenue Next 3Y23.25%
Revenue Next 5Y23.45%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A